XML 77 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Restructuring, Impairment, and Related Charges - Summary of Activity Related to Restructuring Liability (Details) - USD ($)
$ in Millions
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Cost Alignment Plan      
Beginning balance $ 151 $ 157  
Restructuring, impairment, and related charges, net 245 219 $ 156
Non-cash charges (139) (56)  
Cash payments (87) (159)  
Other (40) (10)  
Ending balance 130 151 157
Operating Segments | U.S. Pharmaceutical      
Cost Alignment Plan      
Beginning balance 19 29  
Restructuring, impairment, and related charges, net 35 21 23
Non-cash charges (18) 0  
Cash payments (18) (31)  
Other (7) 0  
Ending balance 11 19 29
Operating Segments | Prescription Technology Solutions      
Cost Alignment Plan      
Beginning balance 4 1  
Restructuring, impairment, and related charges, net 25 4 (1)
Non-cash charges (20) 0  
Cash payments (6) (1)  
Other 0 0  
Ending balance 3 4 1
Operating Segments | Medical-Surgical Solutions      
Cost Alignment Plan      
Beginning balance 3 22  
Restructuring, impairment, and related charges, net 9 4 24
Non-cash charges (5) (1)  
Cash payments (6) (21)  
Other 0 (1)  
Ending balance 1 3 22
Operating Segments | International      
Cost Alignment Plan      
Beginning balance 66 66  
Restructuring, impairment, and related charges, net 76 85 21
Non-cash charges (35) (46)  
Cash payments (28) (31)  
Other (23) (8)  
Ending balance 56 66 66
Corporate      
Cost Alignment Plan      
Beginning balance 59 39  
Restructuring, impairment, and related charges, net 100 105 89
Non-cash charges (61) (9)  
Cash payments (29) (75)  
Other (10) (1)  
Ending balance 59 59 $ 39
Other Accrued Liabilities      
Cost Alignment Plan      
Beginning balance 99    
Ending balance 58 99  
Other noncurrent liabilities      
Cost Alignment Plan      
Beginning balance 52    
Ending balance 36 $ 52  
Disposal Group, Including Discontinued Operation, Liabilities, Current      
Cost Alignment Plan      
Ending balance $ 36